PREDICT 2.0: Invloed therapiekeuze op 5-jaarsoverleving bij patiënten met borstkanker
Samengesteld prognostisch instrument bedoeld om patiënten met borstkanker te informeren en om behandelbesluiten over adjuvante, systemische therapie te ondersteunen.
Details Files & References
Composite
Model author
Version
1.11
Revision date
2020-06-07
Specialty
MeSH terms
  • Breast Cancer
  • Chemotherapy
  • Trastuzumab
  • Surgery
  • Hormonal Antineoplastic Drugs
  • Survival
  • Status
    public
    Share

    Related files

    No related files available

    Supporting Publications

    No supporting publications available
    Results
    Note
    Notes are only visible in the result download and will not be saved by Evidencio

    Composite model

    Conditional information

    Result interpretation

    {{ file.classification }}

    Calculations alone should never dictate patient care, and are no substitute for professional judgement. See our full disclaimer.

    Comments
    Rating
    Comment
    Please enter a comment of rating
    Comments are visible to anyone

    Model feedback

    No feedback yet 1 Comment {{ model.comments.length }} Comments
    Not rated | On {{ comment.created_at }} {{ comment.user.username }} a no longer registered author wrote:
    Underlying models
    5-jaars overleving borstkanker na uitsluitend chirurgische behandeling (PREDICT versie 2.0)
    Research authors: Wishart GC, Azzato EM, Greenberg DC, Rashbass J, Kearins O, Lawrence G, Caldas C, Pharoah PD
    5-jaars overleving borstkanker na chirurgie & hormoontherapie (PREDICT versie 2.0)
    Research authors: Wishart GC, Azzato EM, Greenberg DC, Rashbass J, Kearins O, Lawrence G, Caldas C, Pharoah PD
    5-jaars overleving borstkanker na chirurgie, hormoontherapie & chemotherapie (PREDICT versie 2.0)
    Research authors: Wishart GC, Azzato EM, Greenberg DC, Rashbass J, Kearins O, Lawrence G, Caldas C, Pharoah PD
    5-jaars overleving borstkanker na chirurgie, chemotherapie, hormoontherapie & trastuzumab (PREDICT versie 2.0)
    Research authors: Wishart GC, Azzato EM, Greenberg DC, Rashbass J, Kearins O, Lawrence G, Caldas C, Pharoah PD
    Overlevingswinst van adjuvante hormoontherapie (PREDICT versie 2.0)
    Research authors: Wishart GC, Azzato EM, Greenberg DC, Rashbass J, Kearins O, Lawrence G, Caldas C, Pharoah PD
    Extra overlevingswinst van adjuvante chemotherapie (PREDICT versie 2.0)
    Research authors: Wishart GC, Azzato EM, Greenberg DC, Rashbass J, Kearins O, Lawrence G, Caldas C, Pharoah PD
    Extra overlevingswinst van trastuzumab (PREDICT versie 2.0)
    Research authors: Wishart GC, Azzato EM, Greenberg DC, Rashbass J, Kearins O, Lawrence G, Caldas C, Pharoah PD